Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

Company Overview - Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients globally [17] - The company is advancing research in infectious diseases and orthopedic diseases to address unmet medical needs [17] Product Development - Ocugen has initiated a Phase 2 clinical trial for OCU410, a novel modifier gene therapy candidate for geographic atrophy (GA), which is an advanced stage of dry age-related macular degeneration (dAMD) [14][15] - The ArMaDa Phase 1/2 clinical trial for OCU410 will assess the safety of unilateral subretinal administration in subjects with GA, consisting of a multicenter, open-label, dose-escalation study [7][11] - OCU410 utilizes an adeno-associated virus (AAV) platform to deliver the RORA gene, which plays a role in lipid metabolism and has anti-inflammatory properties [12] Market Context - Geographic atrophy affects approximately 1 million people in the United States, while dry age-related macular degeneration affects around 10 million Americans and over 266 million people worldwide [14][16] - Current FDA-approved anti-complement therapies for GA target only one pathway, providing limited benefits and requiring multiple intravitreal injections over several years [1]